Key Takeaways from ASH 2022: Real-World Data Gets Down to Business
The American Society of Hematology’s 2021 annual meeting showed that real-world data is no longer the new kid on the block – it’s an indispensable part of the toolkit for therapeutic development and clinical research. COTA is proud to be a part of the discussion, contributing research this year for chronic lymphocytic leukemia.
Are Pharma Companies Ready to Harness the Promises of Real-World Data?
Partnering with Impatient Health, we take a comprehensive look at the realities of real-world data and the challenges that pharma companies face in leveraging it to gain actionable insight, based on feedback from executives at well-known, major pharma companies.
This is a key part of our mission to provide the most comprehensive cancer care possible by leveraging the latest advances in data science and technology.
The Power of Collaboration: ASH Showcases COTA’s Real World Data and Research at Annual Meeting
COTA is honored to have contributed to three abstracts accepted for poster presentation at the American Society of Hematology’s 64th Annual Meeting, which cover a range of hematologic cancers. These studies focus on patient- and clinician-reported performance status in Multiple Myeloma, and real-world treatment patterns among patients with newly diagnosed Acute Myeloid Leukemia in the US.
COTA and Google Partner to Use Natural Language Processing to Harness Unstructured Data
We are excited to announce our partnership with Google Cloud to use their Natural Language Processing (NLP) technology to help us better understand the unstructured data in cancer patients’ medical records.
This is a key part of our mission to provide the most comprehensive cancer care possible by leveraging the latest advances in data science and technology.
COTA Announces New Financing from Deerfield Management and Prior Investors To Accelerate Cancer Research and Treatment Innovation
New financing will help COTA expand RWD platform & services to drive more efficient and inclusive drug development.
Early Detection Saves Lives: A Real World Breast Cancer Story
When it comes to cancer, there are a lot of myths and misconceptions out there. But the one thing is for certain: cancer can affect anyone, at any time, and from any background. Hear from one of our own about their battle with breast cancer and how early detection helped them defeat cancer.
It’s Not All about the Benjamins – Other Hurdles Presented by Research Participation, and why Payment won’t Resolve Them
C.K. Wang discusses payment for research participation in this exploratory workshop hosted by the Office for Human Research Protections in the U.S. Department of Health & Human Services.
Real-World Evidence is Now a “True End-to-End Capability” for Life Science Companies, Says Deloitte
Deloitte’s new Real-World Evidence Survey reveals that life sciences companies are now using real-world data (RWD) and real-world evidence (RWE) throughout the product life cycle—from early discovery through commercialization.
RCTs and RWD: What are They and How do They Complement Each Other in Cancer Research?
In this new blog series from COTA and Deloitte, we will explore the expanding role of real-world data in oncology.
Reflecting on Innovation and Hope during Blood Cancer Awareness Month
Every September, the healthcare, life sciences, and patient advocacy communities mark Blood Cancer Awareness Month, a time to focus on raising awareness about leukemia, lymphoma, myeloma, and other cancers that affect the blood or bone marrow.
